 Taizo Nakano
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Aplastic | 7 | 2022 | 30 | 1.830 |
Why?
| | Myelodysplastic Syndromes | 3 | 2021 | 119 | 1.470 |
Why?
| | Bone Marrow Diseases | 3 | 2023 | 18 | 1.110 |
Why?
| | Kasabach-Merritt Syndrome | 2 | 2023 | 4 | 1.030 |
Why?
| | Hematologic Diseases | 2 | 2023 | 55 | 1.020 |
Why?
| | Pancytopenia | 1 | 2023 | 7 | 0.860 |
Why?
| | Chylous Ascites | 1 | 2022 | 6 | 0.820 |
Why?
| | Chylothorax | 1 | 2022 | 11 | 0.820 |
Why?
| | Noonan Syndrome | 1 | 2022 | 17 | 0.790 |
Why?
| | Respiration Disorders | 1 | 2022 | 69 | 0.780 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2022 | 534 | 0.730 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 520 | 0.610 |
Why?
| | Decision Making | 1 | 2020 | 782 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1177 | 0.400 |
Why?
| | Sialic Acids | 1 | 2011 | 7 | 0.390 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 1879 | 0.380 |
Why?
| | Child | 14 | 2023 | 18407 | 0.330 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 256 | 0.320 |
Why?
| | MDS1 and EVI1 Complex Locus Protein | 2 | 2023 | 6 | 0.270 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2011 | 1141 | 0.260 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 113 | 0.250 |
Why?
| | Humans | 24 | 2023 | 114654 | 0.230 |
Why?
| | Hemangioendothelioma | 1 | 2023 | 12 | 0.230 |
Why?
| | Vascular Neoplasms | 1 | 2023 | 15 | 0.220 |
Why?
| | Hemangioma | 1 | 2023 | 41 | 0.220 |
Why?
| | Sarcoma, Kaposi | 1 | 2023 | 68 | 0.210 |
Why?
| | Proto-Oncogenes | 1 | 2022 | 26 | 0.210 |
Why?
| | Fanconi Anemia | 1 | 2022 | 9 | 0.200 |
Why?
| | Ascites | 1 | 2022 | 32 | 0.200 |
Why?
| | Syndrome | 1 | 2023 | 333 | 0.200 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 228 | 0.200 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2022 | 17 | 0.200 |
Why?
| | Drainage | 1 | 2022 | 151 | 0.190 |
Why?
| | Pyrimidinones | 1 | 2022 | 88 | 0.190 |
Why?
| | Genetic Counseling | 1 | 2021 | 65 | 0.190 |
Why?
| | Pyridones | 1 | 2022 | 123 | 0.190 |
Why?
| | Bone Marrow Transplantation | 2 | 2020 | 239 | 0.180 |
Why?
| | Hepatitis | 1 | 2021 | 45 | 0.180 |
Why?
| | Prognosis | 4 | 2020 | 3327 | 0.180 |
Why?
| | Immunosuppressive Agents | 2 | 2021 | 646 | 0.170 |
Why?
| | Zebrafish | 1 | 2023 | 411 | 0.170 |
Why?
| | Survival Rate | 2 | 2020 | 1644 | 0.160 |
Why?
| | Antilymphocyte Serum | 1 | 2019 | 60 | 0.160 |
Why?
| | Time-to-Treatment | 1 | 2020 | 147 | 0.160 |
Why?
| | Hematopoietic System | 1 | 2018 | 8 | 0.160 |
Why?
| | Metformin | 1 | 2022 | 276 | 0.160 |
Why?
| | Sclerotherapy | 1 | 2018 | 19 | 0.160 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 28 | 0.160 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2018 | 35 | 0.150 |
Why?
| | Cyclosporine | 1 | 2019 | 161 | 0.150 |
Why?
| | Lymphatic Abnormalities | 1 | 2018 | 18 | 0.150 |
Why?
| | Doxycycline | 1 | 2018 | 55 | 0.150 |
Why?
| | Transcription Factors | 2 | 2023 | 1528 | 0.150 |
Why?
| | Neoplasms | 1 | 2011 | 2097 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2018 | 222 | 0.140 |
Why?
| | Spleen | 1 | 2018 | 487 | 0.140 |
Why?
| | Patient Selection | 1 | 2020 | 641 | 0.140 |
Why?
| | Skin Neoplasms | 1 | 2023 | 756 | 0.130 |
Why?
| | Infant | 8 | 2022 | 7959 | 0.130 |
Why?
| | Young Adult | 7 | 2022 | 10465 | 0.130 |
Why?
| | Phenotype | 1 | 2023 | 2796 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2021 | 12544 | 0.120 |
Why?
| | Child, Preschool | 7 | 2022 | 9111 | 0.120 |
Why?
| | Adolescent | 7 | 2022 | 17837 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 615 | 0.100 |
Why?
| | Hyperbilirubinemia | 1 | 2012 | 14 | 0.100 |
Why?
| | Induction Chemotherapy | 1 | 2012 | 56 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1355 | 0.100 |
Why?
| | Sialyltransferases | 1 | 2011 | 13 | 0.100 |
Why?
| | Inflammation | 1 | 2022 | 2478 | 0.100 |
Why?
| | Anemia, Hemolytic, Congenital | 1 | 2011 | 1 | 0.090 |
Why?
| | Porphyria, Erythropoietic | 1 | 2011 | 2 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.090 |
Why?
| | Pancreatitis | 1 | 2012 | 107 | 0.090 |
Why?
| | Liver | 1 | 2018 | 1637 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 183 | 0.090 |
Why?
| | Organ Specificity | 1 | 2011 | 268 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2020 | 4411 | 0.090 |
Why?
| | HLA Antigens | 2 | 2022 | 225 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2012 | 125 | 0.090 |
Why?
| | Adult | 7 | 2022 | 30542 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4622 | 0.080 |
Why?
| | Hyperglycemia | 1 | 2012 | 291 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1737 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2011 | 384 | 0.080 |
Why?
| | Patient Care Team | 1 | 2012 | 517 | 0.070 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1121 | 0.070 |
Why?
| | Female | 8 | 2021 | 59488 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2016 | 1862 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2019 | 5044 | 0.060 |
Why?
| | Animals | 4 | 2023 | 31698 | 0.060 |
Why?
| | Vincristine | 1 | 2023 | 98 | 0.050 |
Why?
| | Male | 8 | 2021 | 55579 | 0.050 |
Why?
| | HLA-B Antigens | 1 | 2022 | 56 | 0.050 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2022 | 49 | 0.050 |
Why?
| | Chromosome Inversion | 1 | 2022 | 17 | 0.050 |
Why?
| | Sirolimus | 1 | 2023 | 181 | 0.050 |
Why?
| | Fetal Hemoglobin | 1 | 2021 | 6 | 0.050 |
Why?
| | Mice | 2 | 2022 | 14863 | 0.050 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2022 | 172 | 0.050 |
Why?
| | Eukaryotic Initiation Factors | 1 | 2021 | 9 | 0.050 |
Why?
| | North America | 1 | 2021 | 256 | 0.040 |
Why?
| | Zebrafish Proteins | 1 | 2023 | 246 | 0.040 |
Why?
| | Horses | 1 | 2021 | 96 | 0.040 |
Why?
| | Unrelated Donors | 1 | 2020 | 37 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 243 | 0.040 |
Why?
| | Tacrolimus | 1 | 2021 | 134 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 789 | 0.040 |
Why?
| | Ribosomes | 1 | 2021 | 148 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2537 | 0.040 |
Why?
| | Phosphorylation | 1 | 2023 | 1569 | 0.040 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.040 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 14 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2023 | 685 | 0.040 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 123 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 740 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1342 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 445 | 0.040 |
Why?
| | Middle Aged | 3 | 2022 | 26732 | 0.030 |
Why?
| | Mutation | 2 | 2021 | 3345 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 42 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2021 | 9087 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1373 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1314 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 935 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 993 | 0.030 |
Why?
| | Prospective Studies | 1 | 2023 | 6217 | 0.030 |
Why?
| | Base Sequence | 1 | 2016 | 2114 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4895 | 0.020 |
Why?
| | Uroporphyrinogen III Synthetase | 1 | 2011 | 1 | 0.020 |
Why?
| | Photosensitivity Disorders | 1 | 2011 | 7 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4099 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2635 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 187 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2011 | 284 | 0.020 |
Why?
| | Lung Injury | 1 | 2011 | 197 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3044 | 0.020 |
Why?
| | United States | 1 | 2019 | 12179 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 1728 | 0.010 |
Why?
|
|
Nakano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|